Antiobesity Market Forecast 2024-2033 - Major Trends, Segments And Fastest Growing Regions | F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Antiobesity Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $5.64 billion In 2028 At A CAGR Of 10.7% :

The antiobesity market size has grown rapidly in recent years. It will grow from $3.38 billion in 2023 to $3.76 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing obesity prevalence, awareness and education, lifestyle changes, government initiatives.

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to market expansion, globalization. Major trends in the forecast period include research and development, patient-centric approaches, insurance coverage, technological advancements, digital health and telemedicine, novel drug therapies, bariatric surgery advancements, otc (over-the-counter) solutions, behavioral interventions, nutritional and weight management apps.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=3403&type=smp

Antiobesity Market Major Segments
The antiobesity market covered in this report is segmented -

1) By Drug Class: Peripherally acting anti obesity drugs, Centrally acting anti obesity drugs
2) By Type: Prescription Drugs (Rx), OTC Drugs
3) By Medication: Monotherapies, Polytherapies

Key Driver - Rising Prevalence Rate Of Obesity In The Anti-Obesity Drugs Market

Obesity is a major public health concern globally. Globally, the prevalence rate of obesity is increasing every year. For instance, in May 2022, according to the World Obesity Atlas, a UK-based obesity organization, globally, it is estimated that more than 1 billion people will be suffering from obesity by 2030. This can be attributed to increased consumption of processed and unhealthy food, lack of physical activity, and lack of awareness of the risks of obesity. As a result, the demand for anti-obesity drugs is bound to increase in the future thus, driving the market growth.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=3403&type=smp

Prominent Trend - Product Innovations In The Anti-Obesity Drug Market

Major companies operating in the anti-obesity drugs market are focusing on innovating new products, such as Mounjaro (tirzepatide), to provide reliable services to customers. Mounjaro (tirzepatide) is used as an anti-obesity drug for the treatment of adults with obesity or overweight with weight-related comorbidities. For instance, in October 2022, Eli Lilly and Company,a US-based pharmaceutical company, launched Mounjaro (tirzepatide), approved by the Food and Drug Administration (FDA), a US-based federal agency, as a fast track designation treatment. Mounjaro (tirzepatide) is an injectable form of anti-obesity drug used to help individuals struggling with obesity achieve their weight loss goals. This is used for adults with type 2 diabetes, along with diet and exercise, to improve blood sugar (glucose).

Antiobesity Market Players
Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the anti-obesity market in 2023. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Antiobesity Market Report Structure
3. Antiobesity Market Trends And Strategies
4. Antiobesity Market - Macro Economic Scenario
5. Antiobesity Market Size And Growth
…..
27. Antiobesity Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.